Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of YKST02 in relapsed/refractory multiple myeloma
CTR20262603Phase 2Active
- Sponsor
- Excellos
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of YKST02 in multiple myeloma (MM), sponsored by Excellos. Started Jul 2026; status: active.
02
Drugs
YKST02
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20262603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262603.